Get started
BioAtla, Inc.BioAtla, Inc.BioAtla, Inc.

BioAtla, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

BCAB chart


Full chart

BCAB upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪101.51 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.70 USD
Net income (FY)
‪−123.46 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪39.01 M‬
Beta (1Y)
3.32

Employees


Employees (FY)
65
Change (1Y)
−1 −1.52%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.90 M‬ USD

About BioAtla, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Jay M. Short
Website
bioatla.com
Headquarters
San Diego
Founded
2007
FIGI
BBG00Y6GBT61
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

BCAB news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of BCAB is 2.10 USD — it has decreased by −5.41% in the past 24 hours. Watch BioAtla, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange BioAtla, Inc. stocks are traded under the ticker BCAB.
BCAB stock has risen by 7.69% compared to the previous week, the month change is a 1.94% rise, over the last year BioAtla, Inc. has showed a 25.75% increase.
We've gathered analysts' opinions on BioAtla, Inc. future price: according to them, BCAB price has a max estimate of 13.00 USD and a min estimate of 5.00 USD. Watch BCAB chart and read a more detailed BioAtla, Inc. stock forecast: see what analysts think of BioAtla, Inc. and suggest that you do with its stocks.
BCAB reached its all-time high on Mar 19, 2021 with the price of 76.63 USD, and its all-time low was 1.14 USD and was reached on Jul 9, 2024. View more price dynamics on BCAB chart.
See other stocks reaching their highest and lowest prices.
BCAB stock is 10.78% volatile and has beta coefficient of 3.32. Track BioAtla, Inc. stock price on the chart and check out the list of the most volatile stocks — is BioAtla, Inc. there?
Today BioAtla, Inc. has the market capitalization of ‪101.50 M‬, it has increased by 5.76% over the last week.
Yes, you can track BioAtla, Inc. financials in yearly and quarterly reports right on TradingView.
BioAtla, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
BCAB earnings for the last quarter are −0.22 USD per share, whereas the estimation was −0.41 USD resulting in a 46.77% surprise. The estimated earnings for the next quarter are −0.37 USD per share. See more details about BioAtla, Inc. earnings.
BioAtla, Inc. revenue for the last quarter amounts to ‪11.00 M‬ USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
BCAB net income for the last quarter is ‪−10.59 M‬ USD, while the quarter before that showed ‪−21.07 M‬ USD of net income which accounts for 49.76% change. Track more BioAtla, Inc. financial stats to get the full picture.
No, BCAB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 65.00 employees. See our rating of the largest employees — is BioAtla, Inc. on this list?
Like other stocks, BCAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BioAtla, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BioAtla, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BioAtla, Inc. stock shows the neutral signal. See more of BioAtla, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.